guest ::
| Home > Institute Collections > BN DZNE > BN DZNE-LIS > Nicorandil inhibits neutrophil recruitment in carrageenan-induced experimental pleurisy in mice > print |
| Home > Institute Collections > BN DZNE > BN DZNE-LIS > Nicorandil inhibits neutrophil recruitment in carrageenan-induced experimental pleurisy in mice > print |
| 001 | 284094 | ||
| 005 | 20260126111834.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ejphar.2015.11.034 |2 doi |
| 024 | 7 | _ | |a 0014-2999 |2 ISSN |
| 024 | 7 | _ | |a 1879-0712 |2 ISSN |
| 037 | _ | _ | |a DZNE-2026-00102 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Matsui, Tamires C. |b 0 |
| 245 | _ | _ | |a Nicorandil inhibits neutrophil recruitment in carrageenan-induced experimental pleurisy in mice |
| 260 | _ | _ | |a New York, NY [u.a.] |c 2015 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1769422663_1864 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Nicorandil is a drug characterized by the coupling of a nitric oxide (NO) donor to nicotinamide. We have previously demonstrated that nicotinamide exhibits activity in different models of pain and inflammation. Now, we investigated the effects induced by per os (p.o.) administration of nicorandil (25, 50 or 100mg/Kg) on neutrophil recruitment in a carrageenan-induced model of pleurisy in mice. Effects induced by nicorandil (100mg/kg) were compared with those induced by equimolar doses of nicotinamide (58mg/kg) and N-(2-hydroxyethyl)-nicotinamide (NHN; 79mg/kg). We also investigated whether effects on the production of inflammatory mediators play a role in the activity of nicorandil. P.o. nicorandil, 0.5h before and 1h after the i.pl. injection of carrageenan, reduced neutrophil recruitment. However, equimolar doses of nicotinamide or NHN failed to induce such effect. Single treatment (previous or late) with nicorandil (100mg/Kg, p.o.) also reduced neutrophils recruitment, although to a lesser extent when compared to the double treatment. Nicorandil reduced the concentrations of interleukin-1β, CXCL-1 and prostaglandin E2 in the pleural exudate. Concluding, we demonstrated the activity of nicorandil in a model of pleurisy induced by carrageenan. This activity was characterized by reduction of the neutrophil accumulation and inhibition of production of inflammatory mediators. The effects induced by nicorandil on the leukocytes recruitment and production of inflammatory mediators contribute to a better understanding of its clinical benefits and indicate that these benefits may be due to its vasodilating and anti-inflammatory activities. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: pub.dzne.de |
| 650 | _ | 7 | |a Cytokines |2 Other |
| 650 | _ | 7 | |a Inflammation |2 Other |
| 650 | _ | 7 | |a Neutrophils |2 Other |
| 650 | _ | 7 | |a Nicorandil |2 Other |
| 650 | _ | 7 | |a Nicotinamide |2 Other |
| 650 | _ | 7 | |a Prostaglandin E(2) |2 Other |
| 650 | _ | 7 | |a Anti-Inflammatory Agents |2 NLM Chemicals |
| 650 | _ | 7 | |a Cytokines |2 NLM Chemicals |
| 650 | _ | 7 | |a Eicosanoids |2 NLM Chemicals |
| 650 | _ | 7 | |a Nicorandil |0 260456HAM0 |2 NLM Chemicals |
| 650 | _ | 7 | |a Carrageenan |0 9000-07-1 |2 NLM Chemicals |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Anti-Inflammatory Agents: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Carrageenan: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Cytokines: biosynthesis |2 MeSH |
| 650 | _ | 2 | |a Eicosanoids: biosynthesis |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Leukocytes: drug effects |2 MeSH |
| 650 | _ | 2 | |a Leukocytes: immunology |2 MeSH |
| 650 | _ | 2 | |a Leukocytes: metabolism |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Neutrophil Infiltration: drug effects |2 MeSH |
| 650 | _ | 2 | |a Nicorandil: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Nicorandil: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Pleurisy: chemically induced |2 MeSH |
| 650 | _ | 2 | |a Pleurisy: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Pleurisy: immunology |2 MeSH |
| 650 | _ | 2 | |a Pleurisy: metabolism |2 MeSH |
| 700 | 1 | _ | |a Coura, Giovanna M. E. |b 1 |
| 700 | 1 | _ | |a Melo, Ivo S. F. |b 2 |
| 700 | 1 | _ | |a Batista, Carla R. A. |b 3 |
| 700 | 1 | _ | |a Augusto, Paulo Sérgio A. |b 4 |
| 700 | 1 | _ | |a Godin, Adriana M. |b 5 |
| 700 | 1 | _ | |a Araújo, Débora P. |b 6 |
| 700 | 1 | _ | |a César, Isabela C. |b 7 |
| 700 | 1 | _ | |a Secchim Ribeiro, Lucas |0 P:(DE-2719)9001782 |b 8 |u dzne |
| 700 | 1 | _ | |a Souza, Danielle G. |b 9 |
| 700 | 1 | _ | |a Klein, André |b 10 |
| 700 | 1 | _ | |a de Fátima, Ângelo |b 11 |
| 700 | 1 | _ | |a Machado, Renes R. |b 12 |
| 700 | 1 | _ | |a Coelho, Márcio M. |b 13 |
| 773 | _ | _ | |a 10.1016/j.ejphar.2015.11.034 |g Vol. 769, p. 306 - 312 |0 PERI:(DE-600)1483526-5 |p 306 - 312 |t European journal of pharmacology |v 769 |y 2015 |x 0014-2999 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/284094/files/DZNE-2026-00102_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/284094/files/DZNE-2026-00102_Restricted.pdf?subformat=pdfa |x pdfa |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 8 |6 P:(DE-2719)9001782 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-13 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-13 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-13 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J PHARMACOL : 2022 |d 2024-12-13 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-13 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-13 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J PHARMACOL : 2022 |d 2024-12-13 |
| 920 | _ | _ | |l yes |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-2719)1040260 |
| 980 | 1 | _ | |a EXTERN4VITA |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|